| Dr Cristina S Brotea, MD | |
|
1300 N Highland Ave, Aurora, IL 60506-1451 | |
| (630) 301-7595 | |
| (630) 301-7595 |
| Full Name | Dr Cristina S Brotea |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 29 Years |
| Location | 1300 N Highland Ave, Aurora, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346364502 | NPI | - | NPPES |
| 036107571 | Medicaid | IL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 036107571 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Presence Mercy Medical Center | Aurora, IL | Hospital |
| Copley Memorial Hospital | Aurora, IL | Hospital |
| Entity Name | Cristina S Brotea M D Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568586733 PECOS PAC ID: 0648236240 Enrollment ID: O20041206000645 |
News Archive
An emerging body of research suggests that Alzheimer's disease may be linked to insulin resistance, constituting a third type of diabetes. This model is based on several observations including an increased risk of developing Alzheimer's disease for diabetic patients, and reduced insulin levels in the brain tissue of Alzheimer's disease patients. Though intriguing, the existing evidence does not reveal if defective insulin signaling is causative of Alzheimer's or how insulin resistance impacts cognitive function.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
Halloween is meant to be the spookiest time of year, but no parent wants to experience a real scare on the special night. Stony Brook Children's experts share tips and tricks on how to steer clear from hidden health and safety dangers.
Stand Up To Cancer (SU2C), the Melanoma Research Alliance (MRA) and SU2C's scientific partner, the American Association for Cancer Research (AACR), today announced a new Dream Team dedicated to melanoma research. Jeffrey M. Trent, Ph.D., and Patricia M. LoRusso, D.O., will lead the Dream Team project entitled "Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cristina S Brotea, MD 4107 Easy Cir, Naperville, IL 60564-4431 Ph: (630) 301-7595 | Dr Cristina S Brotea, MD 1300 N Highland Ave, Aurora, IL 60506-1451 Ph: (630) 301-7595 |
News Archive
An emerging body of research suggests that Alzheimer's disease may be linked to insulin resistance, constituting a third type of diabetes. This model is based on several observations including an increased risk of developing Alzheimer's disease for diabetic patients, and reduced insulin levels in the brain tissue of Alzheimer's disease patients. Though intriguing, the existing evidence does not reveal if defective insulin signaling is causative of Alzheimer's or how insulin resistance impacts cognitive function.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
Halloween is meant to be the spookiest time of year, but no parent wants to experience a real scare on the special night. Stony Brook Children's experts share tips and tricks on how to steer clear from hidden health and safety dangers.
Stand Up To Cancer (SU2C), the Melanoma Research Alliance (MRA) and SU2C's scientific partner, the American Association for Cancer Research (AACR), today announced a new Dream Team dedicated to melanoma research. Jeffrey M. Trent, Ph.D., and Patricia M. LoRusso, D.O., will lead the Dream Team project entitled "Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer."
› Verified 8 days ago
Joseph Robert Rojas, Family Medicine Medicare: Medicare Enrolled Practice Location: 2020 Ogden Ave, Aurora, IL 60504 Phone: 630-978-4850 Fax: 630-978-6865 | |
Jurate Kunickaite, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2285 Sequoia Dr, Aurora, IL 60506 Phone: 630-859-6859 | |
Daniel E Hrad, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4205 Westbrook Dr, Aurora, IL 60504 Phone: 630-527-1818 Fax: 630-527-1244 | |
Aruna Galla-pagadala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2285 Sequoia Dr, Aurora, IL 60506 Phone: 630-859-6700 | |
Kuchipudi Veerraju, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 475 N Farnsworth Ave, Aurora Medical Clinic, Aurora, IL 60505 Phone: 630-898-0022 Fax: 630-898-2933 | |
Dr. Robert D. Paras, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2111 Ogden Ave, Aurora, IL 60504 Phone: 630-978-3800 Fax: 630-862-3085 | |
Dr. Mona Habiba Waheed, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2285 Sequoia Dr, Aurora, IL 60506 Phone: 630-859-6700 |